Just in recent memory, investors have had little problem with talking highly-valued med-tech stories like Edwards Lifesciences (NYSE:EW), Intuitive Surgical (NASDAQ:ISRG), and Cepheid (NASDAQ:CPHD) and pushing them even higher on their uncommonly strong revenue growth numbers. Along those same lines, I think HeartWare (NASDAQ:HTWR) could continue to head higher, despite an already rich valuation, on news of strong share/unit growth. That said, investors would do well to notice that the three aforementioned stocks have all had periods where the stock sold off pretty sharply (and pretty quickly), so HeartWare is not for the faint of heart.
Off To A Good Start
HeartWare recently reported results for the fourth quarter of 2012, the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|